NasdaqGM - Nasdaq Real Time Price • USD
Esperion Therapeutics, Inc. (ESPR)
As of 1:00 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 8 | 6 |
Avg. Estimate | 0.05 | -0.21 | -0.4 | 0.05 |
Low Estimate | -0.31 | -0.25 | -1 | -0.67 |
High Estimate | 0.46 | -0.14 | 0.09 | 1.49 |
Year Ago EPS | -0.79 | -0.46 | -2.03 | -0.4 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 8 | 6 |
Avg. Estimate | 84.51M | 42.53M | 265.13M | 391.03M |
Low Estimate | 28.9M | 38M | 174M | 266.1M |
High Estimate | 144.57M | 50.66M | 328.2M | 710.2M |
Year Ago Sales | 24.33M | 25.79M | 116.33M | 265.13M |
Sales Growth (year/est) | 247.40% | 64.90% | 127.90% | 47.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.65 | -0.61 | -0.43 | -0.48 |
EPS Actual | -0.79 | -0.46 | -0.37 | -0.5 |
Difference | -0.14 | 0.15 | 0.06 | -0.02 |
Surprise % | -21.50% | 24.60% | 14.00% | -4.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.05 | -0.21 | -0.4 | 0.05 |
7 Days Ago | 0.05 | -0.21 | -0.4 | 0.05 |
30 Days Ago | 0.02 | -0.2 | -0.44 | 0.04 |
60 Days Ago | -0.04 | 0.1 | -0.28 | 0.51 |
90 Days Ago | -0.07 | 0.06 | -0.34 | 0.33 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | ESPR | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 106.30% | -- | -- | 1.50% |
Next Qtr. | 54.30% | -- | -- | 12.10% |
Current Year | 80.30% | -- | -- | 4.40% |
Next Year | 112.50% | -- | -- | 13.20% |
Next 5 Years (per annum) | 16.90% | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Needham: Buy to Buy | 4/10/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/25/2024 |
Reiterates | Needham: Buy to Buy | 3/25/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
Reiterates | Needham: Buy to Buy | 2/27/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
Related Tickers
DCPH Deciphera Pharmaceuticals, Inc.
14.60
+2.93%
EOLS Evolus, Inc.
11.36
-0.87%
AVDL Avadel Pharmaceuticals plc
18.02
+1.12%
DVAX Dynavax Technologies Corporation
11.21
+0.31%
ELAN Elanco Animal Health Incorporated
13.31
+2.07%
AQST Aquestive Therapeutics, Inc.
4.0800
+3.82%
OPTN OptiNose, Inc.
0.8427
-6.89%
ITCI Intra-Cellular Therapies, Inc.
73.02
+1.23%
SBFM Sunshine Biopharma, Inc.
1.1101
+37.49%
VTRS Viatris Inc.
11.58
+0.92%